Prognostic value of CD44 expression in patients with hepatocellular carcinoma: meta-analysis by unknown
Luo and Tan  Cancer Cell Int  (2016) 16:47 
DOI 10.1186/s12935-016-0325-2
PRIMARY RESEARCH
Prognostic value of CD44 expression 
in patients with hepatocellular carcinoma: 
meta-analysis
Yangkun Luo and Yan Tan*
Abstract 
Background: CD44 has been reported to be involved with tumor growth and metastasis and has also been impli-
cated as a CSC marker in hepatocellular carcinoma (HCC). However, the prognostic value of CD44 still remains 
controversial; hence, we investigated the correlation between CD44 and the clinicopathological features of HCC by 
meta-analysis.
Methods: Identification and review of publications assessing clinical or prognostic significance of CD44 expression in 
HCC until November 1, 2015. A meta-analysis was performed to clarify the association between CD44 expression and 
clinical outcomes.
Results: A total of 14 publications met the criteria and comprised 2235 cases. Analysis of these data showed that 
CD44 expression was not significantly associated with the tumor differentiation (OR 1.48, 95 % confidence interval [CI] 
0.85–2.60, P = 0.17), AFP level of HCC patients (OR 0.83, 95 % CI 0.52–1.33, P = 0.45), or disease-free survival (relative 
risk [RR] 1.15, 95 % CI, 0.85–1.54; P = 0.36). However, in the identified studies, CD44 expression was highly correlated 
with tumor TNM classification (OR 2.38, 95 % CI 1.23–4.60; P = 0.01) and decreased overall survival (RR 1.49, 95 % CI, 
1.26–1.76; P < 0.00001).
Conclusions: This meta-analysis shows CD44 expression in HCC is connected with decreased overall and thus marks 
a worse prognosis.
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Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer worldwide and the most common malignant 
primary tumor in the liver [1]. Despite improvements in 
treatment modalities during the past few decades, the 
prognosis of HCC is still very poor because of frequent 
intrahepatic metastasis and tumor recurrence [2]. It is, 
therefore, desirable to develop a deeper understanding 
of the biology of this disease to adapt current therapeutic 
strategies and to develop therapies that are more effec-
tive. Evidence has recently been accumulating to sup-
port the hypothesis that solid tumors contain a small 
subpopulation of cells called cancer stem-like cells (CSC), 
which exhibit self-renewing capacities and are responsi-
ble for tumor maintenance and metastasis [3] and pos-
sibly for resistance towards chemotherapy and radiation 
therapy [4]. Thus, it is of major importance to investigate 
CSCs associated with cancer progression as they may be 
important factors in determining the clinical outcomes 
of cancer. Furthermore, CSC markers, such as CD44, 
CD133 and ALDH1, are potential indicators of HCC 
prognosis [5–7]. Among these CSC markers, CD44 is the 
most frequently reported in HCC. Several studies simi-
larly utilised CD44 positivity to isolate cells with stem 
cell-like and cancer-initiating properties from other can-
cer cells [8–10].
The CD44 receptor is a typeItransmembrane glycopro-
tein that was initially identified as a leukocyte antigen 
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[11]. The alternative splicing of variable exons of CD44 
results in abundant variants, which are denoted CD44v, 
and the isoform with no variable exons in the mRNA is 
named CD44 standard (CD44s) [12]. The smallest, stand-
ard isoform is CD44s, which is generally expressed on 
vertebrate cells, while CD44v is only expressed on some 
epithelial cells [13]. CD44 is the major hyaluronan (HA) 
receptor [13], and CD44 bound to HA has been proven 
to participate in various tumor biological activities, 
including tumor progression, metastasis and prolifera-
tion [14, 15].
However, the correlations between CD44 and clinico-
pothological features of HCC and theirs prognostic val-
ues are still controversial. Some concluded that CD44 
expression had no influence on survival [16, 17]. While 
others reported that CD44 expression was predictive of 
decreased survival outcome for HCC [18–20]. In order to 
evaluate this question, we conducted a systematic review 
and meta-analysis to determine the association between 
the expression of HCC and clinicopathological features 
and prognosis of HCC patients.
Methods
Search strategy
A systematic literature search was performed in the 
electronic databases Pubmed, Embase and Wanfang 
until November of 2015. Search terms included “CD44”, 
“hepatocellular carcinoma” or “HCC” or “liver cancer” or 
“liver tumor” or “liver neoplasms” or “hepatocellular car-
cinoma”. The titles and abstracts of potential references 
were carefully scanned to exclude irrelevant articles. The 
remaining articles were evaluated to identify research 
that contained the topic of interest, and full texts were 
reviewed in depth afterwards.
Selection criteria
The studies included in the present meta-analysis were 
randomised controlled studies or observational studies 
(case–control or cohort) that evaluated the association 
between the expression of CD44 and the prognosis or 
the clinical data of HCC. Studies were included if they (1) 
focused on the clinical features or prognosis of HCC; (2) 
analysed the correlation of CD44 expression with clini-
cal features and survival outcomes [(disease-free survival 
(DFS) or overall survival (OS)]. Articles were excluded 
on the basis of the following criteria: (1) non-association 
studies; (2) review articles or case reports; (3) association 
studies for other diseases; (4) overlapped research; (5) 
insufficient data on survival.
All evaluations were independently performed by 
two reviewers to ensure the accurate inclusion of stud-
ies. When several studies containing overlapping data 
emerged, the one with the largest data set was adopted. 
If the original data were not provided in the text, we con-
tacted the authors for the data necessary to conduct the 
meta-analysis.
Data extraction
All data were extracted by two independent reviewers. 
Disagreements in data extraction were resolved by reach-
ing a consensus in accordance with the original article. 
The following relevant data were extracted in a prede-
fined table: author, publication year, patient’s country, 
tumor stage, number of patients, research technique used 
and the choice of cutoff scores for the definition of posi-
tive staining or staining intensity. Considering that some 
studies displayed survival data with a Kaplan–Meier 
curve, we used GetData Graph Digitizer 2.26 (http://get-
data-graph-digitizer.com/) to digitise and extract survival 
data.
Statistical analysis
Stata version 12.0 (StataCorp LP, TX) was used in this 
meta-analysis. The statistical analysis was performed 
according to the guidelines proposed by the meta-anal-
ysis of observational studies in Epidemiology group. 
ORs with 95 % CI were used to evaluate the correlation 
between CD44 expression and clinicopathological fea-
tures, including tumor TMN classification, tumor grade 
and AFP level in HCC patients. RRs with 95 % CI were 
used to evaluate correlation between CD44 expression 
and 5-year DFS and 5-year OS. The heterogeneity among 
studies was measured using the Q test and I2 test. A 
fixed-effects model was used in the absence of significant 
heterogeneity; a random-effect model was used other-
wise. Begg’s and Egger’s tests were performed to identify 
the potential publication bias. P  <   0.05 was considered 
to indicate statistical significance. All P values are two-
tailed. Sub-group analyses were performed to investigate 
the association of CD44 expression with clinical features 
and prognosis in terms of method, cutoff of staining, 
sample size, follow-up time and subtypes of the CD44 
family. Furthermore, a sensitivity analysis was performed 
to examine the robustness of the pooled results.
Results
Description of studies
A total of 227 articles were selected for the meta-analysis 
by browsing the databases PubMed, Embase and Wan-
fang, of which 202 were excluded after reviewing the title 
and abstract, eleven articles were excluded after review-
ing the full publications (Fig. 1). Eventually, a total of 14 
studies with 2235 patients, who fulfilled all of the inclu-
sion criteria, were considered for the analysis [16–29]. All 
patients in the eligible studies were determined by patho-
logical stage. All of the studies reported the prognostic 
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value of CD44 expression for survival in patients with 
HCC. Estimation using survival curves were segregated 
according to either DFS or OS. A RR on DFS or OS could 
be extracted for all enrolled studies. The characteristics 
of the included studies are listed in Table 1.
Correlation of CD44 expression with clinicopathological 
parameters
The association between CD44 and several clinicopatho-
logical parameters is illustrated in Fig.  2. CD44 expres-
sion was highly correlated with tumor TNM classification 
(I+II vs. III+IV)(OR 2.38, 95 % CI 1.23–4.60, P = 0.01, 
fixed-effect) (Fig.  2a). However, CD44 expression was 
not significantly associated with tumor differentiation 
(G1 + G2 vs. G3) (OR 1.48, 95 % CI 0.85–2.60, P = 0.17, 
fixed-effect) (Fig. b) and AFP level of HCC patients (OR 
0.83, 95 % CI 0.52–1.33, P = 0.45, fixed-effect) (Fig. 2c).
CD44 expression and 5‑year survival outcome
Fourteen studies investigating OS were pooled into the 
meta-analysis. As shown in Fig.  3, there was significant 
association between CD44 expression and OS (RR, 1.49, 
95 % CI, 1.26–1.76; P < 0.00001) with significant hetero-
geneity (I2 = 74 %, P < 0.0001). We also performed sub-
group analysis by method, cutoff of staining, sample size, 
follow-up time or subtypes of the CD44 family in HCC. 
Significant association was also detected in all stratified 
analysis (Table 2).
CD44 expression and DFS in HCC
Seven studies identifying DFS were pooled into the meta-
analysis. As shown in Fig.  4, there was no significant 
association between CD44 expression and DFS (RR, 1.15, 
95 % CI, 0.85–1.54; P = 0.36) with significant heteroge-
neity (I2 = 86 %, P < 0.00001).
Fig. 1 Literature search strategy and selection of articles
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In fact, three out of seven studies have concluded CD44 
expression as an unfavorable prognostic factor in HCC 
patients.
Publication bias
The funnel plots presented no evidence of publication 
bias in the studies of either outcome (Fig. 5a, b). No evi-
dence for significant publication bias was found in OS 
(Egger’s test, P = 0.151) and DFS (Egger’s test, P = 0.805) 
studies.
Sensitivity analysis
In order to test for a bias introduced by the low numbers 
of available eligible publications we performed a sen-
sitivity analysis. For this a single study involved in the 
meta-analysis was omitted for each round of analysis to 
investigate the influence of the individual data set of the 
particular study to the pooled ORs. We found that that 
pooled RRs of OS and DFS was not significantly changed, 
suggesting the robustness of our results (Fig. 6a, b).
Discussion
To the best of our knowledge, this is the first meta-
analysis of published studies to evaluate the association 
between total CD44 expression (including CD44, CD44 s 
and CD44v6) and prognosis in HCC. Heterogeneity anal-
ysis and sensitivity analysis were also critically performed 
to ensure the epidemiological credibility of this meta-
analysis. The present results indicate that CD44 expres-
sion is positively associated with higher tumor TNM 
stage, as well as poor OS for patients with HCC. How-
ever, we find no significant association between CD44 
positivity and differentiation degree, AFP level or DFS 
for patients with HCC. This trend suggests that CD44 
can function as a prognostic factor for predicting the out-
comes of HCC patients. Therefore, our data imply that 
elevated CD44 expression can contribute to HCC devel-
opment and progression, and the detection of the CD44 
aberrations may be useful for identifying poor prognoses 
in patients with HCC. For future studies, co-expression 
of hepatic CSC markers associated with patient survival 
Table 1 Characteristics of the included studies
Study Patient’s 
country
















Endo et al. 
[18]
Japan Asian 2000 ND ND IHC 107 17–80 80 >0 % 
staining
OS
Huang et al. 
[22]
China Asian 2001 1995–1999 I–IV IHC 51 36–72 48 >0 % 
staining
OS
Su et al. [27] China Asian 2006 1996–1999 I–IV IHC 40 32–70 36 >0 % 
staining
OS
Yang et al. 
[28]
China Asian 2008 1997–2000 I–IV IHC 302 26–75 121 >10 % 
staining
OS; DFS
Zhang et al. 
[21]
China Asian 2008 2001–2004 I–IV IHC 50 21–68 ND >20 % 
staining
OS
Peng et al. 
[23]
China Asian 2010 2005–2006 ND IHC 76 19–69 36 >25 % 
staining
OS
Ryu et al. 
[17]
Korea Asian 2011 1990–2003 I–IV IHC 260 ND 137 >10 % 
staining
OS; DFS
Tovuu et al. 
[25]
Japan Asian 2012 2005–2009 I–IV RT–PCR 48 ND 48 Median OS; DFS
Mima et al. 
[16, 19]
Japan Asian 2012 2004–2007 I–IV IHC 150 ND 60 >0 % 
staining
OS; DFS
Zhou et al. 
[24]
China Asian 2012 2007–2010 I–III RT–PCR 323 ND 74 Median OS; DFS
Mima et al. 
[16, 19]
Japan Asian 2012 2004–2007 I–IV IHC 235 ND 60 >50 % 
staining
OS; DFS
Chen et al. 
[26]
China Asian 2014 2005–2008 I–IV IHC 387 ND 96 >10 % 
staining
OS
Cao et al. 
[29]
China Asian 2014 2005–2011 ND IHC 46 22–79 85 >25 % 
staining
OS
Hu et al. [20] China Asian 2014 2006–2007 I–III IHC 160 29–72 84 >10 % 
staining
OS; DFS
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may be more meaningful for clinical application in HCC. 
Several studies have shown that CSC-related factors, 
including CD133, EPCAM, and CD90, are associated 
with HCC progression [30–32]. In addition, CSCs have 
major phenotypic and functional heterogeneity which 
may help distinguish them from cancer cells, and may 
be of potential benefit in the development of anti-cancer 
therapies to improve clinical outcomes.
A previous study showed that CD44-positive tumor 
cells have CSC properties, such as self-renewal and tum-
origenicity [33]. Expression of CD44 has been closely 
linked to tumor progression, metastasis, and treatment 
resistance processes in various cancers [34–36]. In par-
ticular, CD44 is closely associated with aggressive behav-
ior and correlates with poor prognosis in a variety of 
human malignancies, and it has been shown to regulate 
malignant transformation by inducing tumor cell pro-
liferation, adhesion, and migration [37]. Furthermore, 
the prognostic value of CD44 expression in HCC is yet 
to be elucidated. The results of our study indicated that 
increased CD44 expression correlated with poor OS of 
HCC patients. However, contrasting results were also 
reported. For instance, Horiguchi et  al. reported that 
CD44 expression correlates with favorable prognosis 
in breast cancer [38]. In addition, Liang et  al. reported 
that gastrointestinal stromal tumor patients with higher 
expressions of CD44 survived longer and had lower 
recurrence rates [39]. These conflicting results suggest an 
elusive role of CD44 in cancer progression and metasta-
sis. Thus, more prospective studies are needed to draw a 
definite conclusion.
Although our study revealed the positive correla-
tion between CSCs marker CD44 and tumor TNM 
stage and survival of patients with HCC, CD44 itself as 
a biomarker has its limitations on predicting prognosis 
and clinicopathological parameters in patients. Firstly, 
overall survival (OS) and disease free survival (DFS) 
were determined from unadjusted RRs in the published 
Fig. 2 Forest plot depiction of CD44 expression and OR for clinical pathologic features. Clinicopathological parameters investigated are (a) TMN 
classification, (b) tumor grade (c)AFP level
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papers, and RRs from the survival curves might be 
less reliable those that from direct analysis of variance. 
Ideally, measurements should be directly obtained 
from the statistical data in published papers and then 
adjusted by using other prognostic factors. Secondly, 
in the assessment of biomarkers, the use of a standard 
threshold is of great importance. Although immunohis-
tochemistry was the most commonly applied method, 
differences in cut-off values for positive CD44 expression 
may have contributed to the observed heterogeneity. 
Fig. 3 Forest plot illustrates the association between CD44 expression and OS of HCC
Table 2 Associations between CD44 expression and OS of HCC grouped by selected factors
POR P value for odds ratio
Stratified analysis Studies Odds ratio Model Heterogeneity
OR (95 % CI) POR I2 (%) P
OS 15 1.49 (1.26–1.76) <0.00001 Random 74 <0.00001
Method
 IHC 13 1.48 (1.22–1.78) <0.0001 Random 76 <0.00001
 RT-PCR 2 1.64 (1.32–2.04) <0.0001 Fixed 0 0.99
Cut off
 >10 % 3 1.63 (1.05–2.54) 0.03 Random 55 0.11
 ≤10 % 10 1.45 (1.17–1.80) 0.0007 Random 80 <0.00001
 Median 2 1.64 (1.32–2.04) <0.0001 Fixed 0 0.99
Sample size
 >50 11 1.38 (1.17–1.64) 0.0002 Random 75 <0.0001
 ≤50 4 2.26 (1.64–3.12) <0.00001 Fixed 30 0.23
Follow-up(m)
 >60 8 1.53 (1.22–1.92) 0.0002 Random 74 0.0004
 ≤60 7 1.46 (1.12–1.90) 0.005 Random 76 0.0004
Subtypes of the CD44 family
 CD44 4 1.35 (1.16–1.56) 0.0001 Fixed 24 0.27
 CD44v6 6 1.51 (1.11–2.05) 0.008 Random 86 <0.00001
 CD44s 5 1.59 (1.10–2.29) 0.01 Random 74 0.004
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Thirdly, the OR of each study is generally small and the 
conclusion might be affected by one or two reports with 
large ORs. All of these factors might partly influence the 
significance of CD44 expression in the survival and the 
clinicopathological analysis. Fourth, the survival data are 
achieved directly, calculated from the available data, or 
extracted from the K-M curves in the articles. The lat-
ter two methods are less reliable than direct analysis of 
primary data [40].
In summary, this meta-analysis indicated that CD44 
expression was associated with tumor TNM stage in 
HCC. Moreover, positive CD44 expression was associ-
ated with a worse outcome than CD44-negative expres-
sion, and CD44 was an independent factor associated 
with reduced survival. The relative simplicity in the meth-
odology for using CD44 expression for the identification 
Fig. 4 Analysis of CD44 expression and DFS among included studies
Fig. 5 Begg’s funnel plot estimated the publication bias of the 
included literature for OS (a) and DFS (b)
Fig. 6 Sensitivity analysis of all the studies assessing OS (a) and DFS 
(b)
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of hepatic CSC suggests that this marker should be fur-
ther evaluated for their potential use in the identification 
of hepatic CSC in clinical practice.
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